Search Results - targeted+therapy%2ftargeted+therapy

5 Results

Sort By:

Compositions Comprising NDGA Derivatives and Sorafenib and their Use in the Treatment of Cancer

INVENTION NOVELTYJHU investigators have combined the NDGA derivatives M4N and sorafenib to create a pharmaceutical composition that inhibits cancer cell growth. This novel drug combination has increased cytotoxic activity and inhibits growth of HCC human cancer cells in a dose-dependent manner.VALUE PROPOSITIONInvestigators have discovered a drug composition...

Published: 3/13/2025 | Inventor(s): Jong ho Chun, David Mold, Christopher Ruland, Yu-Chuan Liang, Ru Chih Huang

Keywords(s): Antagonists/Inhibitors, Cancers, Combination, Disease Indication, Novel, Predicted Novelty, Small Molecules, Targeted Therapy/Targeted Therapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities

PHARMACEUTICAL AGENTS TARGETING CANCER STEM CELLS

UNMET NEEDChronic environmental exposure induces cancer stem cells (CSCs) with SOX2 overexpression, one of the most important CSC factor for urothelial cancer (UC). COX2 and YAP1 coordinately regulate SOX2 expression, and mutually compensate for the reduction of expression of SOX2 to maintain CSCs. Thus targeting the COX2/YAP/SOX2 signaling axis eliminates...

Published: 3/13/2025 | Inventor(s): Mohammad Hoque, David Sidransky, Akira Oki

Keywords(s): Antagonists/Inhibitors, Bladder Cancer, Cancers, Combination, Disease Indication, Non-novel, Predicted Novelty, Small Molecules, Targeted Therapy/Targeted Therapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type, Urothelial Carcinoma

Category(s): Clinical and Disease Specializations > Oncology > Bladder Cancer, Clinical and Disease Specializations > Oncology > Urothelial Carcinoma, Clinical and Disease Specializations > Rare Diseases, Clinical and Disease Specializations > Urology, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Targets

Reprograming the Cancer Cells with Epigenetic Therapy (DNA Demethylating Agents and Histone Deacetylase Inhibitors) Sensitizes Multiple Cancers to PARP Inhibitors

Combinatorial Drug Therapy for CancersJHU REF: [C12345]Invention novelty: a combinatorial drug therapy for leukemia, ovarian, breast and lung cancers by targeting both epigenetic and DNA repair pathways.Value PropositionConventional forms of cancer drug therapy are limited in their results once the cancers exhibit resistance to existing drug regimens....

Published: 3/13/2025 | Inventor(s): Nidal Muvarak, Feyruz Rassool, Carine Robert, Stephen Baylin

Keywords(s): Antagonists/Inhibitors, Cancers, Combination, Disease Indication, Non-novel, Predicted Novelty, Repurposed, Small Molecules, Targeted Therapy/Targeted Therapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Rapid Induction of Human Cancer Cell Death by Synergistic Treatment of Tetra-O-Methyl Nordihydroguaiaretic Acid (M4N, Terameprocol) with 7-Hydroxystaurosporine (UCN-01)

Value Proposition: Tetra-O-methyl nordihydroguaiaretic acid (M4N, EM1421, Terameprocol), a novel transcription inhibitor, is an effective anticancer agent with excellent safety profile (Smolewski, P. Idrugs 11, 204-214, 2008). In the current study, we report an enhancement of anticancer activities of M4N in combination with 7-hydroxystaurosporine (UCN-01),...

Published: 3/13/2025 | Inventor(s): Kotohiko Kimura, Ru Chih Huang

Keywords(s): Antagonists/Inhibitors, Cancers, Combination, Disease Indication, Non-novel, Off-the-shelf, Predicted Novelty, Small Molecules, Targeted Therapy/Targeted Therapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

PNU-120596 and 3-(2,4-dimethoxybenzylidene) Anabaseine (GTS-21) (both nAchRa7 agonists) and Methyllycaconitine (anAchRa7 antagonist), are Highly Effective Drugs in Therapy of Ulcerative Colitis (UC) and Crohn's Disease (CD)

C10382: Breakthrough Therapeutic for Inflammatory Bowel Diseases (IBD)Novelty: This technology identifies a nicotinic acetylcholine receptor isoform (nAChR7) that has a prevalent role in affecting Inflammatory Bowel Disease (IBD), as well as several agonist/antagonists to nAChR7, that are highly effective in both the prevention and therapy of ulcerative...

Published: 3/13/2025 | Inventor(s): Philip Alex, Michael Centola, Xuhang Li

Keywords(s): Chronic Inflammatory Diseases, Combination, Crohn's disease, Crohn's Disease, Disease Indication, Gastrointestinal Disorders, Inflammatory Bowel Disease, Inflammatory Bowel Disease (IBD), Natural compounds, Non-novel, Off-the-shelf, Predicted Novelty, Small Molecules, Targeted Therapy/Targeted Therapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type, Ulcerative Colitis, Ulcerative Colitis (UC)